|
Onyx Names Scott M. Freeman Vice President, Clinical Development and Helen S. Kim Senior Vice President, Corporate Development RICHMOND, Calif., March 19 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) announced today the appointment of Scott M. Freeman to Vice President, Clinical Development. Dr. Freeman joins the company from Schering-Plough Research Institute where he held the position of Clinical Project Director of Oncology. ``We are very excited to have someone with Scott`s experience and reputation in oncology clinical research join Onyx,`` said Leonard E. Post, Senior Vice President, Research and Development of Onyx. ``Scott brings to us his in-depth experience in oncology clinical development and gene therapy. I am extremely pleased to welcome him to the Onyx management team.`` At Schering-Plough, Dr. Freeman was responsible for the management of several oncology-based clinical programs. Prior to joining Schering-Plough, Dr. Freeman held the positions of Associate Professor and Medical Director of the Blood Center at Tulane University where he managed various programs in research and development of gene therapy for cancer, in addition to managing Tulane`s Blood Center. He also held the position of Adjunct Associate Professor at the University of Rochester and served as a guest researcher at the National Institutes of Health (NIH) from 1986-1990. Dr. Freeman`s career at NIH and academia was distinguished by a fundamental discovery, the bystander effect of prodrug activating gene therapy, and his proposal of one of the first human gene therapy protocols to the NIH Recombinant DNA Advisory Committee. He holds a medical degree from University of Nevada and a Bachelor of Arts degree from University of Colorado. The company also announced the promotion of Helen S. Kim to Senior Vice President, Corporate Development. Ms. Kim joined Onyx in December 1999 as Vice President, Corporate Development from Protein Design Laboratories, Inc. (PDLI), where she served as Vice President, Marketing and Project Management. Prior to joining PDLI, Ms. Kim was Vice President, Strategic Marketing at Chiron Corporation. ``Helen has been instrumental in guiding Onyx in active corporate development initiatives,`` said Hollings Renton, Chairman and Chief Executive Officer. ``Her contributions will continue to be invaluable as Onyx continues to seek strategic partnerships and build a successful oncology business.`` Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, CI-1042 (ONYX-015). CI-1042 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of different additional cancer indications. For more information about CI-1042 and Onyx`s pipeline and activities, visit Onyx`s Web site at www.onyx-pharm.com. This press release contains forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials and changes in the status of the companies collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports with the Securities and Exchange Commission, including but not limited to its Annual Report in Form 10-K, may affect the actual results achieved by the company. SOURCE: Onyx Pharmaceuticals, Inc. |
|
| aus der Diskussion: | onyx pharmaceut. im juhu musterdepot! |
| Autor (Datum des Eintrages): | panik (19.03.01 13:51:32) |
| Beitrag: | 21 von 229 (ID:3128906) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |